Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

Sean P. Stroup, Kerrin Palazzi-Churas, Ryan Kopp, J. Kellogg Parsons

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Objective: • To determine if the adverse events (AEs) of benign prostatic hyperplasia (BPH) have declined in tandem with increased use of oral therapy. Materials and methods • We used the Nationwide Inpatient Sample, a 20% sample of USA community hospitals, weighted to estimate national numbers to characterize the prevalence of AEs of BPH from 1998 to 2008. • We calculated the age-adjusted prevalence of BPH and associated conditions and analyzed prevalence trends with regression modelling. Results: • Of 134 million estimated eligible discharges during the study period, 7 464 730 (5.6%) had either a primary or secondary diagnosis of BPH. • The age-adjusted prevalence of BPH among all hospitalizations, irrespective of primary diagnosis, increased from 4.3% to 8% (P <0.001) during the study period. • The age-adjusted prevalence of BPH as a primary diagnosis decreased from 0.88% to 0.48% (P <0.001). • Discharges for BPH surgery decreased 51% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.45-0.54, P-trend 400% (OR 4.28, 95% CI 3.22-5.71, P-trend

Original languageEnglish (US)
Pages (from-to)84-87
Number of pages4
JournalBJU International
Volume109
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

    Fingerprint

Keywords

  • benign prostatic hyperplasia (BPH)
  • epidemiology
  • Nationwide Inpatient Sample (NIS)
  • outcomes

ASJC Scopus subject areas

  • Urology

Cite this